Abstract & Overview

GHRP‑6 (Growth Hormone Releasing Peptide‑6) is a synthetic hexapeptide and one of the earliest members of the growth hormone secretagogue (GHS) class. It acts as a potent agonist of the ghrelin receptor (GHS‑R1a), triggering both endocrine and metabolic responses in research models. By mimicking endogenous ghrelin signaling, GHRP‑6 provides a tool for studying growth hormone release, cellular metabolism, and tissue repair mechanisms. Its biochemical profile and receptor interactions make it an important compound for exploring neuroendocrine regulation and energy homeostasis in laboratory settings.

Molecular Pharmacology

GHRP‑6 is a hexapeptide with the sequence His‑D‑Trp‑Ala‑Trp‑D‑Phe‑Lys‑NH₂. It belongs to the same structural family as GHRP‑2, Hexarelin, and Ipamorelin but exhibits a unique receptor activation pattern. Its primary target, the growth hormone secretagogue receptor type 1a (GHS‑R1a), is a G‑protein–coupled receptor (GPCR) that mediates both calcium‑dependent and cAMP‑linked signaling cascades. Through this receptor, GHRP‑6 influences pituitary growth hormone release and peripheral metabolic responses. Studies highlight its dual capacity to activate endocrine and paracrine signaling pathways involved in cell proliferation, metabolism, and stress adaptation.

Ghrelin Receptor Signaling Pathway

GHRP‑6 acts as an exogenous ligand for GHS‑R1a, a receptor expressed predominantly in the hypothalamus, pituitary gland, pancreas, and gastrointestinal tract. Upon binding, GHRP‑6 activates Gq/11 proteins, leading to phospholipase C (PLC) stimulation and the generation of inositol triphosphate (IP₃) and diacylglycerol (DAG). This signaling cascade increases intracellular calcium concentrations and activates protein kinase C (PKC), which promotes vesicular growth hormone release from pituitary somatotrophs. In addition to this canonical pathway, GHRP‑6 signaling interacts with MAPK/ERK, PI3K/Akt, and AMPK networks, linking the peptide to broader effects on metabolism and mitochondrial regulation.

Endocrine and Metabolic Research

In controlled studies, GHRP‑6 has been shown to stimulate pulsatile growth hormone secretion, elevating circulating insulin‑like growth factor‑1 (IGF‑1) concentrations through hepatic synthesis. These responses make it valuable for studying somatotropic axis regulation and growth‑related signaling. Beyond endocrine actions, GHRP‑6 influences glucose metabolism, fatty acid oxidation, and mitochondrial biogenesis through AMPK activation and improved cellular energy utilization. Research models indicate that chronic GHS‑R1a activation may contribute to enhanced metabolic flexibility and adaptive responses under nutrient stress conditions.

Cellular Regeneration and Stress Response

GHRP‑6 has been used to study cytoprotective and regenerative mechanisms in a variety of tissues, including skeletal muscle, liver, and neural systems. Its signaling activity modulates apoptosis, autophagy, and oxidative stress pathways, leading to reduced cellular injury and improved tissue repair. GHRP‑6’s influence on mitochondrial integrity and reactive oxygen species (ROS) control highlights its relevance in studies of cellular longevity and metabolic adaptation. Additionally, its engagement with the ghrelin receptor system contributes to anti‑inflammatory signaling through NF‑κB inhibition and cytokine modulation.

Comparative Signaling: GHRP‑6 vs. GHRP‑2 and Azelaprag

While GHRP‑6 and GHRP‑2 share similar receptor targets, they differ in potency and receptor bias. GHRP‑2 demonstrates higher affinity for GHS‑R1a but shorter duration, while GHRP‑6 offers a broader receptor activation profile with enhanced metabolic modulation. Compared with Azelaprag—a non‑peptide ghrelin receptor agonist—GHRP‑6 represents a classic peptide model for studying ligand‑receptor conformational signaling and the kinetics of GPCR activation. Together, these compounds help define how different molecular frameworks influence GHS‑R1a‑mediated pathways and downstream gene expression.

Research Applications in Metabolism and Growth

Due to its dual anabolic and metabolic actions, GHRP‑6 serves as a model compound for studying growth hormone physiology, energy metabolism, and cellular recovery mechanisms. In muscle and hepatic tissue, it promotes protein synthesis, glycogen replenishment, and oxidative balance. Studies also investigate its effects on circadian rhythm regulation, appetite control, and gut‑brain axis communication through peripheral ghrelin receptor activation. These findings position GHRP‑6 as a versatile research tool for examining interconnected neuroendocrine and metabolic networks.

Summary

GHRP‑6 is a synthetic peptide that continues to play a significant role in ghrelin receptor and growth hormone secretagogue research. Its receptor interactions extend beyond GH release, encompassing mitochondrial regulation, energy metabolism, and cellular resilience. By linking endocrine control with metabolic adaptation, GHRP‑6 provides a valuable model for understanding GHS‑R1a signaling and its broader implications in physiological and cellular research.

Educational & Research Disclaimer

This article is for educational and scientific research purposes only. No therapeutic claims or usage recommendations are provided. Compounds referenced are not approved for human use and are intended solely for controlled laboratory experimentation.

FAQ:

PMID:

• PMID: 7542028
  Discovery and characterization of growth hormone–releasing peptides.
• PMID: 8651140
  Growth hormone secretagogues and their mechanism of action at the pituitary level.
• PMID: 10473535
  Identification and cloning of the growth hormone secretagogue receptor (GHS-R).
• PMID: 10920360
  Ghrelin as the endogenous ligand for the GHS-R receptor.
• PMID: 12050244
  Signal transduction pathways activated by GHRP-6 and ghrelin receptor agonists.
• PMID: 15240662
  Role of GHS-R activation in endocrine and metabolic regulation.

RELATED SEARCHES:

Orforglipron : Oral Small-Molecule GLP-1 Receptor Agonist and Incretin Pathway Modulation

GHRP‑2 : Pituitary Axis Modulation, Ghrelin Receptor Activation, and Cellular Recovery Research

ACE‑031 : Myostatin Inhibition, Muscle Hypertrophy, and Regenerative Research

Azelaprag : Ghrelin Receptor (GHS‑R1a) Activation, Growth Hormone Secretagogue Signaling, and Energy Balance Research Pathways

Follistatin: Myostatin-Regulated Pathways and Advanced Muscle Research

• 

GHRP-6 5mg

$45.00

GHRP-6 is a synthetic growth hormone–releasing peptide studied for its interaction with ghrelin receptors and pathways related to growth hormone signaling and metabolic regulation. For research use only.

GHRP-6 5mg quantity

Add to cart

SKU: TPC-GHRP6-5MG

Category: Peptides, Hormonal & Growth Signaling

Tags: appetite signaling peptide, endocrine signaling peptide, gh release peptide, gh secretagogue, ghrelin receptor agonist, ghrp-6, ghrp6 peptide, ghsr peptide, growth hormone peptide, hormone pathway peptide, metabolic research peptide, pituitary signaling

Abstract & Overview

Cartalax is a tissue-specific bioregulatory peptide classified within the cytomedin family and studied for its regulatory influence on cartilage tissue. Derived conceptually from cartilage-associated peptide fractions, Cartalax is investigated for its role in modulating chondrocyte gene expression, extracellular matrix maintenance, and age-associated connective tissue decline. Unlike general repair peptides that act through growth signaling pathways, Cartalax operates primarily at the genomic and epigenetic level, supporting long-term structural homeostasis of cartilage tissue. As a research compound, Cartalax provides a focused model for studying peptide-based regulation of connective tissue aging.

Background: Cartilage Biology and Aging

Cartilage is a specialized connective tissue characterized by low cellularity, limited vascularization, and slow regenerative capacity. Chondrocytes are responsible for maintaining the extracellular matrix composed primarily of collagen type II, aggrecan, and proteoglycans. With aging and mechanical stress, cartilage undergoes progressive degeneration marked by reduced matrix synthesis, altered gene expression, and increased susceptibility to breakdown. Research into cartilage-specific bioregulators such as Cartalax aims to clarify how genomic regulation may support cartilage integrity over time.

Cytomedins and Tissue-Specific Regulation

Cytomedins are short regulatory peptides, typically consisting of two to four amino acids, that exhibit organotropism and tissue specificity. Cartalax belongs to this class and demonstrates preferential regulatory effects within cartilage and connective tissue environments. Rather than acting as classical signaling molecules, cytomedins influence transcriptional and translational processes within target cells, providing sustained modulation of tissue function. This mechanism differentiates Cartalax from peptides that stimulate acute growth or inflammatory responses.

Molecular Classification and Structure

Cartalax is characterized as a short bioregulatory peptide optimized for genomic interaction within chondrocytes. Its minimal amino acid composition facilitates cellular uptake and nuclear access in experimental models. Unlike large structural proteins or growth factors, Cartalax does not serve as a building block of cartilage matrix but instead functions as a regulator of gene expression patterns governing matrix synthesis and turnover.

Mechanism of Action: Chondrocyte Gene Regulation

The primary mechanism attributed to Cartalax involves modulation of gene expression within chondrocytes. Research indicates that Cartalax influences transcriptional activity related to collagen synthesis, proteoglycan production, and matrix organization. By stabilizing RNA synthesis and protein translation, Cartalax supports balanced extracellular matrix maintenance and may counteract age-related shifts toward catabolic signaling in cartilage tissue.

Epigenetic Effects and Chromatin Modulation

Cartalax has been associated with epigenetic regulatory effects, including modulation of chromatin accessibility and histone modification states within chondrocytes. These epigenetic actions enable sustained expression of cartilage-specific genes critical for tissue resilience. Such genomic-level regulation distinguishes Cartalax from short-acting signaling peptides and aligns it with other tissue-specific bioregulators focused on long-term homeostasis.

Role in Cartilage Integrity and Connective Tissue Homeostasis

Through its genomic regulatory actions, Cartalax contributes to maintenance of cartilage integrity and connective tissue balance. Experimental observations suggest improved preservation of cartilage architecture and cellular phenotype in models of degenerative stress. This regulatory role extends to broader connective tissue systems, where coordinated gene expression is essential for mechanical stability and tissue function.

Comparative Context: Cartalax vs General Repair Peptides

Cartalax differs fundamentally from general repair peptides such as BPC-157 or TB-500, which primarily influence angiogenesis, cell migration, and acute repair signaling. While those peptides address injury response, Cartalax focuses on normalization of gene expression within cartilage cells, supporting structural maintenance rather than rapid regeneration. This distinction positions Cartalax as a foundational bioregulator for connective tissue research.

Integration With Other Bioregulators

Within the bioregulator framework, Cartalax is often studied alongside peptides such as Vilon, Thymalin, Pancragen, and Cardiogen. Vilon provides systemic coordination, while Cartalax delivers cartilage-specific genomic regulation. Together, these peptides illustrate a hierarchical model of bioregulation in which universal and tissue-specific regulators act synergistically to maintain organism-wide homeostasis.

Research Findings and Experimental Models

Experimental studies involving Cartalax have demonstrated normalization of chondrocyte gene expression, preservation of extracellular matrix components, and reduced markers of cartilage degradation. In vitro models show enhanced stability of cartilage-specific transcriptional programs, while in vivo observations support Cartalax’s role in maintaining connective tissue structure under age-related stress.

Limitations and Open Research Questions

Despite promising experimental findings, important questions remain regarding Cartalax’s precise molecular targets, long-term genomic effects, and interactions with mechanical loading and inflammatory pathways. Further research is required to define its role across different cartilage types and to elucidate its integration with broader connective tissue regulatory networks.

Summary

Cartalax represents a cartilage-specific bioregulator peptide that offers critical insight into genomic regulation of connective tissue homeostasis. By influencing chondrocyte gene expression and epigenetic stability, Cartalax supports long-term maintenance of cartilage integrity. Its study contributes to a deeper understanding of peptide-based strategies for addressing age-associated connective tissue decline.

Educational & Research Disclaimer

This document is provided for educational and scientific research purposes only. No medical, therapeutic, or usage claims are made. Cartalax and related compounds are not approved for human use and are intended solely for controlled laboratory and academic investigation.

FAQ:

PMID:

• PMID: 12928777
  Khavinson V, Morozov VG. Peptide bioregulators and their role in gene expression regulation.
• PMID: 14738556
  Khavinson V et al. Short peptides regulate gene expression and protein synthesis in human cells.
• PMID: 17654843
  Khavinson V, Linkova N. Peptide regulation of chondrocyte function and connective tissue aging.
• PMID: 21728784
  Cartilage extracellular matrix regulation and aging-related degeneration mechanisms.
• PMID: 23809343
  Epigenetic mechanisms involved in cartilage homeostasis and degeneration.
• PMID: 15234339
  Collagen synthesis regulation in chondrocytes and matrix maintenance.

RELATED ARTICLES:

FOXO4-DRI : Targeting Cellular Senescence Through p53–FOXO4 Disruption and Senolytic Research

B7‑33 : Relaxin Pathway Modulation and Fibrosis Regulation in Cellular Signaling Research

Cardiogen: Short Peptide Bioregulator for Cardiac and Myocardial Tissue Research

ProstaMax : Short Peptide Bioregulator for Prostate Tissue Regulatory Research

GHK-Cu — Research Article

Abstract & Overview

Orforglipron is a synthetic, non-peptide small molecule designed to activate the glucagon-like peptide‑1 (GLP‑1) receptor through oral administration. Unlike traditional incretin agonists derived from peptide backbones, Orforglipron represents a chemically engineered approach to engaging class B G‑protein–coupled receptors. Research surrounding this compound focuses on its ability to modulate metabolic signaling pathways involved in appetite regulation, glucose homeostasis, and energy balance. Orforglipron serves as a key model for investigating non‑peptide incretin receptor activation and the expanding role of small molecules in metabolic biology.

Molecular Classification and Pharmacology

Orforglipron belongs to the category of orally bioavailable small‑molecule receptor agonists. Structurally distinct from peptide incretins, it does not rely on amino acid sequences or peptide folding for receptor engagement. Its chemical architecture is optimized for gastrointestinal stability and systemic absorption. From a pharmacological perspective, Orforglipron demonstrates that GLP‑1 receptor activation can be achieved through non‑peptide ligand binding, challenging historical assumptions that peptide structure is required for effective incretin signaling.

Mechanism of Action

The mechanism of Orforglipron centers on direct activation of the GLP‑1 receptor, a class B GPCR involved in metabolic regulation. Upon receptor binding, Orforglipron stimulates Gs protein signaling, leading to increased intracellular cyclic adenosine monophosphate (cAMP) levels and downstream activation of protein kinase A (PKA). This signaling cascade influences transcriptional activity, metabolic enzyme regulation, and neural signaling pathways associated with appetite and energy balance. Due to its small‑molecule nature, Orforglipron may exhibit signaling bias, selectively engaging specific intracellular pathways relative to peptide-based agonists.

Gut–Brain Axis and Central Metabolic Signaling

GLP‑1 receptors are expressed throughout the gastrointestinal tract and central nervous system, forming a critical communication network known as the gut–brain axis. Orforglipron’s oral bioavailability allows it to participate in this signaling network by influencing peripheral and central receptor populations. Research models indicate that GLP‑1 receptor activation within this axis contributes to appetite regulation, satiety signaling, and coordinated metabolic responses, positioning Orforglipron as a useful compound for studying neuro‑metabolic integration.

Comparative Insights: Small Molecules vs Peptide GLP‑1 Agonists

Compared to peptide‑based GLP‑1 agonists, Orforglipron differs in molecular weight, stability, and synthesis. Peptide agonists require structural modifications to resist enzymatic degradation, whereas Orforglipron’s chemical composition inherently resists proteolysis. While peptide agonists more closely mimic endogenous GLP‑1, small‑molecule agonists such as Orforglipron offer alternative receptor engagement profiles and manufacturing efficiencies. These distinctions provide valuable comparative insight into how molecular format influences receptor signaling and biological outcomes.

Research Findings and Experimental Models

Preclinical and early research models investigating Orforglipron focus on receptor affinity, signaling kinetics, and metabolic pathway modulation. Experimental data highlight its capacity to activate canonical GLP‑1 signaling pathways while maintaining oral stability. Ongoing studies evaluate its effects on metabolic biomarkers, receptor desensitization dynamics, and long‑term signaling behavior. Orforglipron is frequently used as a reference compound in research exploring non‑peptide incretin agonism.

Implications for Metabolic Research

Orforglipron’s development has broader implications for metabolic and endocrine research. It demonstrates that small molecules can effectively target class B GPCRs traditionally dominated by peptide ligands. This has encouraged expanded investigation into oral incretin modulators, receptor signaling bias, and alternative approaches to metabolic pathway regulation. Orforglipron also serves as a conceptual bridge between peptide‑based biology and chemically driven pharmacological design.

Summary

Orforglipron represents a significant advancement in incretin research as a non‑peptide, orally active GLP‑1 receptor agonist. Its ability to engage metabolic signaling pathways without peptide structure underscores the importance of receptor biology over molecular format alone. As a research compound, Orforglipron continues to inform studies on gut–brain signaling, metabolic regulation, and the future design of small‑molecule GPCR agonists.

Educational & Research Disclaimer

This document is provided for educational and scientific research purposes only. No medical, therapeutic, or usage claims are made. Compounds discussed are not approved for human use and are intended solely for controlled laboratory and academic investigation.

PMID:

• PMID: 37344954
  Orforglipron (LY3502970), a novel, oral non-peptide GLP-1 receptor agonist: Phase 1a safety, tolerability, PK/PD in humans
• PMID: 40544435
  Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes
• PMID: 41275875
  Orforglipron, an oral small-molecule GLP-1 receptor agonist, for obesity treatment in adults with type 2 diabetes (ATTAIN-2)
• PMID: 41337725
  Comment on Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes
• PMID: 40808573
  Orforglipron improves markers of β-cell function and insulin sensitivity in type 2 diabetes
• PMID: 37852529
  Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonist orforglipron
• PMID: 37351564
  Daily oral GLP-1 receptor agonist Orforglipron for adults

RELATED SEARCHES:

Adipotide (Prohibitin‑Targeting Peptide): Mitochondrial Apoptosis, Angiogenesis Inhibition, and Adipose Tissue Research

Cagrilintide : Amylin Receptor Activation, Energy Homeostasis, and Appetite Regulation in Research Models

CagriSema : Dual Amylin and GLP‑1 Receptor Research Synergy in Metabolic and Appetite Regulation Models

Mazdutide : Dual GLP‑1 and Glucagon Receptor Activation in Metabolic and Lipid Regulation Research

Apelin : APJ Receptor Signaling, Cardiovascular Regulation, and Metabolic Research Pathways

Abstract & Overview

FOXO4-DRI is a rationally designed peptide-based research compound developed to investigate mechanisms of cellular senescence and selective elimination of senescent cells. It is engineered to disrupt the interaction between the transcription factor FOXO4 and the tumor suppressor protein p53, a molecular complex that contributes to the survival of senescent cells. By interfering with this interaction, FOXO4-DRI provides a powerful experimental tool for studying senescence-associated apoptosis, aging biology, and tissue homeostasis. Research on FOXO4-DRI has positioned it as a foundational compound in senolytic science, offering insight into how dysfunctional cells evade programmed cell death.

Background: Cellular Senescence and Aging Biology

Cellular senescence is a stable state of irreversible cell-cycle arrest that occurs in response to DNA damage, telomere shortening, oxidative stress, oncogenic signaling, and mitochondrial dysfunction. While senescence initially serves a protective role by preventing malignant transformation, the accumulation of senescent cells over time contributes to chronic inflammation, tissue degeneration, and age-associated decline. Senescent cells exhibit a characteristic senescence-associated secretory phenotype (SASP), marked by the release of pro-inflammatory cytokines, chemokines, growth factors, and proteases that disrupt tissue microenvironments and impair regenerative capacity.

The Role of FOXO4 in Senescent Cell Survival

FOXO4 belongs to the Forkhead box O (FOXO) family of transcription factors, which regulate genes involved in cell cycle control, oxidative stress resistance, DNA repair, and apoptosis. In senescent cells, FOXO4 plays a paradoxical role by contributing to cellular survival rather than elimination. Elevated FOXO4 expression in senescent cells promotes nuclear retention of p53, preventing its translocation to mitochondria where it would otherwise initiate apoptosis. This FOXO4–p53 interaction effectively shields senescent cells from programmed cell death, allowing their persistence within tissues.

p53 Signaling and Apoptotic Control

p53 is a central regulator of genomic integrity and cellular fate, orchestrating responses to DNA damage through transcription-dependent and transcription-independent mechanisms. Under apoptotic conditions, p53 can translocate to mitochondria and interact with BCL-2 family proteins, leading to mitochondrial outer membrane permeabilization and caspase activation. In senescent cells, however, the FOXO4–p53 complex restricts this apoptotic pathway, maintaining senescent cell viability despite extensive molecular damage. Disruption of this interaction restores p53’s apoptotic potential.

Design and Molecular Structure of FOXO4-DRI

FOXO4-DRI is a modified peptide derived from the FOXO4 protein interface responsible for p53 binding. It incorporates a D-retro-inverso (DRI) design, in which the amino acid sequence is reversed and composed of D-amino acids rather than the naturally occurring L-amino acids. This structural modification confers resistance to proteolytic degradation while preserving the spatial orientation necessary for molecular recognition. As a result, FOXO4-DRI exhibits enhanced stability and sustained activity in experimental systems.

Mechanism of Action

The mechanism of FOXO4-DRI centers on competitive inhibition of the FOXO4–p53 interaction. By binding to p53 with high affinity, FOXO4-DRI displaces endogenous FOXO4, releasing p53 from its nuclear sequestration. Freed p53 is then able to translocate to mitochondria, where it activates intrinsic apoptotic pathways. This process selectively induces apoptosis in senescent cells, which are uniquely dependent on FOXO4-mediated p53 retention for survival.

Selectivity for Senescent Cells

A defining feature of FOXO4-DRI is its selectivity. Non-senescent cells typically express lower levels of FOXO4 and rely less on FOXO4–p53 interactions for survival. Consequently, disruption of this pathway disproportionately affects senescent cells while sparing healthy, proliferating cells. This selectivity distinguishes FOXO4-DRI from non-specific cytotoxic agents and underpins its importance in senolytic research.

Preclinical Research Findings

Experimental studies using cellular and animal models have demonstrated that FOXO4-DRI induces apoptosis in senescent fibroblasts, endothelial cells, and other senescent cell populations. In aged animal models, treatment with FOXO4-DRI reduced senescent cell burden, improved tissue function, and enhanced physical performance metrics. These findings support the hypothesis that targeted removal of senescent cells can reverse aspects of age-related tissue dysfunction.

FOXO4-DRI and the Senescence-Associated Secretory Phenotype

By eliminating senescent cells, FOXO4-DRI indirectly suppresses the SASP, reducing the pro-inflammatory milieu that contributes to chronic tissue damage. This effect has significant implications for understanding how senescence drives systemic aging processes and age-associated diseases. Reduction of SASP factors may improve intercellular communication, stem cell niche integrity, and regenerative signaling.

Implications for Aging and Regenerative Research

FOXO4-DRI has become a cornerstone compound for investigating the causal role of senescent cells in aging. Its use has accelerated research into senolytics as a strategy for restoring tissue homeostasis, enhancing regenerative capacity, and extending healthspan. Beyond aging, FOXO4-DRI provides insight into fibrotic disease, metabolic dysfunction, and degenerative conditions where senescent cell accumulation plays a pathogenic role.

Comparative Context Within Senolytic Research

FOXO4-DRI is mechanistically distinct from other senolytic approaches that target anti-apoptotic pathways such as BCL-2 inhibition. Rather than broadly sensitizing cells to apoptosis, FOXO4-DRI exploits a senescence-specific survival mechanism. This precision makes it a valuable comparative tool for dissecting senolytic specificity, efficacy, and downstream biological effects.

Limitations and Ongoing Research Questions

Despite its promise, FOXO4-DRI remains a research compound with unanswered questions regarding long-term effects, tissue-specific responses, and optimal delivery strategies. Ongoing studies aim to clarify how senescent cell heterogeneity influences sensitivity to FOXO4-DRI and how senolytic interventions interact with immune-mediated clearance mechanisms.

Summary

FOXO4-DRI represents a paradigm-shifting approach to senescence research by directly targeting the molecular interactions that allow senescent cells to evade apoptosis. Through disruption of the FOXO4–p53 complex, FOXO4-DRI selectively induces death of senescent cells, offering profound insight into aging biology and tissue regeneration. As a research tool, it continues to shape the emerging field of senolytics and redefine strategies for addressing age-associated cellular dysfunction.

Educational & Research Disclaimer

This document is provided for educational and scientific research purposes only. No medical, therapeutic, or usage claims are made. FOXO4-DRI and related compounds are not approved for human use and are intended solely for controlled laboratory and academic investigation.

FAQ:

PMID

• PMID: 27641501 — FOXO4-DRI selectively induces apoptosis in senescent cells and restores tissue homeostasis
• PMID: 28467800 — Cellular senescence and the FOXO4–p53 axis in aging
• PMID: 26657150 — Targeting senescent cells: mechanisms and biological relevance
• PMID: 30778102 — Senolytics in aging and age-related disease research

RELATED SEARCHES:

B7‑33 : Relaxin Pathway Modulation and Fibrosis Regulation in Cellular Signaling Research

Cardiogen: Short Peptide Bioregulator for Cardiac and Myocardial Tissue Research

ProstaMax : Short Peptide Bioregulator for Prostate Tissue Regulatory Research

Humanin : Mitochondrial-Derived Peptide Signaling, Cellular Stress Resistance, and Neuroprotective Research Pathways

GHK-Cu — Research Article

Abstract & Overview

GHRP‑2 (Growth Hormone Releasing Peptide‑2) is a synthetic hexapeptide classified within the family of growth hormone secretagogues (GHS). It is a potent agonist of the ghrelin receptor (GHS‑R1a) and has been extensively studied as a model compound for growth hormone release, pituitary sensitization, and cellular metabolic regulation. By mimicking the physiological actions of endogenous ghrelin, GHRP‑2 allows for the exploration of neuroendocrine signaling pathways that link the hypothalamus, pituitary gland, and peripheral tissues. Compared with GHRP‑6, GHRP‑2 demonstrates higher receptor affinity and more pronounced growth hormone–releasing activity, making it a valuable tool in controlled research examining somatotropic axis regulation and energy metabolism.

Molecular Pharmacology

GHRP‑2 is a hexapeptide with the sequence D‑Ala‑D‑His‑D‑Phe‑D‑Trp‑Lys‑Val‑NH₂. It functions as a selective agonist of the GHS‑R1a receptor, a G‑protein–coupled receptor expressed in the hypothalamus, pituitary gland, pancreas, and other metabolic tissues. Activation of GHS‑R1a triggers both calcium‑dependent and cAMP‑dependent intracellular cascades, leading to exocytosis of growth hormone from somatotroph cells. The peptide’s pharmacokinetic profile is characterized by rapid receptor binding and a robust amplitude of GH secretion in pulsatile models, distinguishing it from GHRP‑6 in potency and duration.

Receptor Mechanism of Action

Upon binding to GHS‑R1a, GHRP‑2 activates Gq/11 proteins, leading to phospholipase C (PLC) activation and the generation of inositol triphosphate (IP₃) and diacylglycerol (DAG). These molecules promote intracellular calcium release and activate protein kinase C (PKC), which triggers growth hormone secretion at the pituitary level. In parallel, GHRP‑2 influences other signaling networks, including MAPK/ERK and PI3K/Akt, promoting cellular survival, metabolism, and adaptive energy responses. The peptide’s capacity to modulate both endocrine and metabolic functions has made it an important compound for studying the cross‑talk between neuroendocrine and mitochondrial pathways.

Endocrine and Metabolic Regulation

Research models demonstrate that GHRP‑2 elevates plasma GH concentrations through direct pituitary stimulation and indirect hypothalamic activation. This GH release subsequently upregulates hepatic insulin‑like growth factor‑1 (IGF‑1) synthesis, driving anabolic processes such as protein synthesis, lipid oxidation, and tissue repair. Additionally, GHRP‑2 has been shown to modulate glucose metabolism and mitochondrial respiration via AMPK activation and improved substrate utilization. These effects make it a valuable agent for exploring the metabolic underpinnings of energy homeostasis in both central and peripheral systems.

Comparative Analysis: GHRP‑2 vs. GHRP‑6

While both GHRP‑2 and GHRP‑6 activate GHS‑R1a and promote GH release, they exhibit key pharmacological differences. GHRP‑2 possesses a higher receptor binding affinity and faster onset of action, leading to greater GH amplitude in dose‑response studies. GHRP‑6, however, demonstrates broader metabolic influence and mild orexigenic activity due to its secondary receptor interactions. Comparative data suggest that GHRP‑2 is more selective and potent for pituitary‑specific GH release, whereas GHRP‑6 exerts a wider systemic effect on energy balance and tissue metabolism.

Cellular Recovery and Regenerative Research

Beyond endocrine functions, GHRP‑2 has been studied for its effects on cellular recovery and oxidative stress modulation. In vitro and in vivo research models show that GHRP‑2 enhances mitochondrial membrane potential, reduces reactive oxygen species (ROS), and stabilizes cellular redox balance. Its anti‑inflammatory influence through NF‑κB pathway suppression and cytokine regulation further supports its potential as a model for stress adaptation and tissue recovery studies. These findings underscore its value in investigating the intersection between peptide signaling, mitochondrial health, and regenerative cellular mechanisms.

Summary

GHRP‑2 is a potent ghrelin receptor agonist that exemplifies the relationship between neuroendocrine signaling, energy metabolism, and cellular protection. Its ability to induce growth hormone release, enhance mitochondrial efficiency, and regulate redox balance has made it a foundational compound for research into somatotropic and metabolic pathways. By comparing its receptor bias and mechanistic profile to analogs such as GHRP‑6 and Azelaprag, researchers can gain valuable insight into GHS‑R1a signaling and its systemic implications for metabolic homeostasis.

Educational & Research Disclaimer

This article is for educational and scientific research purposes only. No therapeutic claims or usage recommendations are provided. Compounds referenced are not approved for human use and are intended solely for controlled laboratory experimentation.

FAQ:

PMID

• PMID: 8380393 – Discovery and characterization of growth hormone–releasing peptides acting independently of GHRH.
• PMID: 9000608 – Identification of synthetic GH secretagogues and their role in pituitary growth hormone release.
• PMID: 9204910 – Demonstration of GHRP-2–induced GH secretion via hypothalamic and pituitary mechanisms.
• PMID: 9725909 – Evidence of ghrelin receptor involvement in growth hormone secretagogue signaling.
• PMID: 10490927 – Comparative analysis of GHRP-2 and other GH secretagogues on endocrine hormone release.
• PMID: 11786544 – Review of growth hormone secretagogues and their physiological and cellular signaling effects.

RELATED ARTICLES:

Abstract & Overview

Ara‑290 is a synthetic 11‑amino‑acid peptide derived from the tertiary structure of erythropoietin (EPO), specifically the region associated with tissue‑protective signaling rather than hematopoiesis. It functions as a selective activator of the innate repair receptor (IRR), a heteroreceptor complex formed by the erythropoietin receptor (EPOR) and CD131 (β common receptor). By engaging this receptor pathway, Ara‑290 exerts potent anti‑inflammatory, anti‑apoptotic, and tissue‑protective effects without stimulating red blood cell production. This property has made Ara‑290 a leading research tool for studying cellular repair, immune modulation, and neuroprotection.

Molecular Pharmacology

Ara‑290 is composed of the amino acid sequence MQAWLTSPVDSAGPV, corresponding to the helix B surface region of the erythropoietin molecule. This truncated form eliminates the erythropoietic binding domain but preserves affinity for the EPOR/CD131 receptor complex. Its activity is mediated by transient and selective activation of the IRR, which promotes intracellular survival signaling cascades including JAK2/STAT3, PI3K/Akt, and NF‑κB modulation. Through these pathways, Ara‑290 supports mitochondrial integrity, reduces oxidative stress, and enhances cellular resilience under hypoxic or inflammatory conditions.

Mechanism of Action

Ara‑290’s mechanism centers on selective IRR activation, distinguishing it from full‑length EPO and recombinant analogs that stimulate erythropoiesis. Binding to the EPOR/CD131 heteroreceptor activates JAK2 phosphorylation, leading to downstream STAT3 and Akt signaling. This activation inhibits pro‑inflammatory cytokine release, suppresses apoptosis, and facilitates tissue remodeling. Additionally, Ara‑290 has been shown to enhance endothelial function, increase nitric oxide bioavailability, and promote vascular stabilization—key contributors to its regenerative and cytoprotective profile.

Tissue Protection and Regenerative Research

Extensive studies demonstrate Ara‑290’s ability to protect neural, cardiac, renal, and hepatic tissues from injury. In preclinical models of ischemia, Ara‑290 reduces infarct size, mitigates oxidative damage, and improves tissue perfusion. Its anti‑inflammatory signaling contributes to microvascular stability and attenuation of leukocyte adhesion. In cardiac and renal models, Ara‑290 prevents fibrosis by downregulating TGF‑β and preserving mitochondrial homeostasis. Collectively, these findings support its value as a model compound for studying cytoprotection and tissue regeneration through non‑hematopoietic EPO signaling pathways.

Neuropathy and Pain Signaling

One of the most promising research applications of Ara‑290 lies in neuropathic and neuroinflammatory conditions. In small fiber neuropathy models, Ara‑290 enhances peripheral nerve regeneration and reverses pain hypersensitivity by restoring axonal mitochondrial function. It also modulates microglial activation and inflammatory cytokine production in central and peripheral nervous tissue. Through these mechanisms, Ara‑290 serves as a model compound for understanding nerve repair, neuroimmune regulation, and pain transmission in chronic injury contexts.

Comparative Signaling: Ara‑290 vs. EPO and HBSP

Full‑length erythropoietin activates both homodimeric EPOR and the heteromeric EPOR/CD131 complex, resulting in erythropoiesis and tissue protection, respectively. In contrast, Ara‑290 exclusively targets the latter, thereby isolating the cytoprotective effects of EPO without hematologic stimulation. Helix‑B Surface Peptide (HBSP) shares structural homology and functional overlap with Ara‑290, but differs slightly in stability and receptor affinity. Both peptides are instrumental in defining the IRR pathway’s role in non‑hematopoietic EPO signaling, emphasizing receptor‑specific tissue protection as a research focus.

Summary

Ara‑290 represents a paradigm shift in the study of erythropoietin‑derived peptides by dissociating tissue‑protective signaling from erythropoiesis. Through selective activation of the EPOR/CD131 complex, it enables investigation into anti‑inflammatory, anti‑apoptotic, and regenerative processes across multiple organ systems. Its robust mechanistic foundation and reproducible effects in neural and microvascular models make Ara‑290 a key reference compound for exploring targeted peptide therapeutics and cellular resilience pathways.

Educational & Research Disclaimer

This article is for educational and scientific research purposes only. No therapeutic claims or usage recommendations are provided. Compounds referenced are not approved for human use and are intended solely for controlled laboratory experimentation.

FAQ:

PMID:

PMID: 16888043 – Brines M, Cerami A. Discovery of erythropoietin’s tissue-protective and non-hematopoietic biological functions.

PMID: 17644734 – Identification of the erythropoietin–CD131 heteroreceptor responsible for tissue protection without erythropoiesis.

PMID: 20172558 – Evaluation of Ara-290 as a non-erythropoietic erythropoietin analog in neuropathic pain models.

PMID: 22954607 – Characterization of Ara-290 as a novel erythropoietin-derived peptide with cytoprotective and anti-inflammatory properties.

PMID: 23878234 – Clinical investigation of Ara-290 in small fiber neuropathy associated with sarcoidosis.

PMID: 24316313 – Review of receptor mechanisms mediating erythropoietin’s tissue-protective signaling pathways.

Related Searches:

Selank : Tuftsin-Derived Heptapeptide and Neuromodulatory Research Pathways

Tesofensine: Monoamine Reuptake Inhibition, Metabolic Energy Regulation, and Neuroendocrine Research Mechanisms

Oxytocin : Neuroendocrine Signaling, Social Cognition, and Systemic Regulatory Pathways in Research Models

Humanin : Mitochondrial-Derived Peptide Signaling, Cellular Stress Resistance, and Neuroprotective Research Pathways

Glutathione: Cellular Redox Homeostasis, Antioxidant Defense, and Detoxification Pathways in Research Models

Abstract & Overview

Adipotide, also known as FTPP (Fat‑Targeted Proapoptotic Peptide), is a synthetic bifunctional peptide designed to selectively target the blood vessels that supply white adipose tissue. It operates through a dual‑domain structure that recognizes prohibitin (PHB) and annexin A2 (ANX2) expressed on adipose vasculature, initiating mitochondrial apoptosis within endothelial cells. By disrupting adipose‑specific vasculature, Adipotide reduces local blood flow to adipocytes, leading to apoptosis and resorption of fat tissue. This compound has been widely used in research exploring adipose remodeling, vascular targeting, and metabolic reprogramming mechanisms.

Molecular Pharmacology

Adipotide’s design integrates a targeting sequence and an effector sequence connected by a glycine‑glycine linker. Its structure, CKGGRAKDC‑GG‑D[KLAKLAK]₂, enables tissue specificity and mitochondrial disruption in targeted cells. The N‑terminal CKGGRAKDC motif binds to prohibitin and annexin A2 on adipose endothelial cells, while the C‑terminal D[KLAKLAK]₂ motif penetrates mitochondria, causing membrane depolarization and apoptosis. This dual‑action architecture distinguishes Adipotide from non‑specific apoptotic peptides by providing precise localization and reduced systemic toxicity in experimental models.

Mechanism of Action

The pharmacodynamic activity of Adipotide begins with its selective binding to prohibitin‑rich adipose vasculature. Following receptor engagement, the mitochondrial‑disrupting domain translocates into endothelial cells, compromising mitochondrial membrane potential and inducing caspase‑dependent apoptosis. This process leads to vascular rarefaction—reducing adipose tissue perfusion—and subsequent adipocyte atrophy and apoptosis. The result is a decrease in total white adipose mass accompanied by improved systemic metabolic parameters, including enhanced insulin sensitivity and lipid oxidation.

Metabolic and Endocrine Research Findings

In non‑human primate studies, Adipotide has demonstrated significant reductions in body fat percentage and improvements in glucose homeostasis without stimulating β‑adrenergic receptors. This mechanism differentiates it from traditional lipolytic agents by avoiding central nervous system activation. Research also indicates normalization of fasting insulin, reduced hepatic lipid accumulation, and improved AMPK‑related signaling in adipose and skeletal muscle tissues. These findings position Adipotide as an experimental model for dissecting adipose‑vascular‑metabolic interactions in obesity and metabolic syndrome.

Mitochondrial Pathway and Cellular Remodeling

Adipotide’s downstream effects are mediated through mitochondrial depolarization, release of cytochrome c, and activation of caspase‑3 and ‑9. This pathway results in targeted apoptosis and subsequent tissue remodeling via macrophage‑driven clearance of apoptotic adipocytes. Furthermore, Adipotide alters local oxidative stress balance, transiently increasing reactive oxygen species (ROS) to activate adaptive mitochondrial biogenesis in non‑adipose tissues. These combined effects contribute to improved metabolic flexibility and cellular adaptation under energy‑restricted conditions.

Comparative Mechanistic Insights

Compared to other fat‑modulating compounds such as AOD‑9604 and 5‑Amino‑1MQ, Adipotide exerts its effects through vascular apoptosis rather than hormone receptor or enzyme modulation. Where AOD‑9604 enhances lipolysis and 5‑Amino‑1MQ modulates NAD⁺ metabolism, Adipotide focuses on angiogenesis inhibition and mitochondrial disruption. This unique approach provides a complementary research model for studying energy balance, adipose signaling, and vascular integrity in metabolic disease pathways.

Summary

Adipotide represents a novel vascular‑targeted research compound that integrates tissue selectivity with mitochondrial‑mediated apoptosis. Its targeted mechanism allows researchers to explore the relationships between adipose vasculature, energy metabolism, and cellular remodeling. As studies expand into mitochondrial and angiogenic signaling, Adipotide continues to serve as a foundational tool in understanding metabolic adaptation and fat mass regulation at the molecular level.

Educational & Research Disclaimer

This article is for educational and scientific research purposes only. No therapeutic claims or usage recommendations are provided. Compounds referenced are not approved for human use and are intended solely for controlled laboratory experimentation.

FAQ:

PMID:

• PMID: 19305393 — Prohibitin as a vascular targeting marker in adipose tissue
• PMID: 19597507 — Adipose tissue vasculature targeting and apoptosis-inducing peptides
• PMID: 20194764 — Mitochondrial disruption mechanisms in targeted endothelial cells
• PMID: 22496128 — Angiogenesis inhibition and adipose remodeling via targeted peptides

RELATED SEARCHES:

Cagrilintide : Amylin Receptor Activation, Energy Homeostasis, and Appetite Regulation in Research Models

CagriSema : Dual Amylin and GLP‑1 Receptor Research Synergy in Metabolic and Appetite Regulation Models

Mazdutide : Dual GLP‑1 and Glucagon Receptor Activation in Metabolic and Lipid Regulation Research

AICAR : AMPK Activation, Cellular Energy Sensing, and Exercise‑Mimetic Signaling in Research Models

Apelin : APJ Receptor Signaling, Cardiovascular Regulation, and Metabolic Research Pathways

Abstract & Overview

ACE‑031 is a recombinant fusion protein that functions as a soluble activin receptor type IIB (ActRIIB) analog, designed to inhibit the biological activity of myostatin (GDF‑8) and related ligands such as activin A and GDF‑11. As a myostatin pathway inhibitor, ACE‑031 serves as a model compound for studying skeletal muscle hypertrophy, regeneration, and energy metabolism. By preventing myostatin from binding to its receptor, ACE‑031 promotes muscle fiber growth and differentiation, offering a valuable research platform for understanding muscle physiology and tissue regeneration.

Molecular Pharmacology

ACE‑031 consists of the extracellular ligand‑binding domain of the activin receptor type IIB fused to the Fc domain of human IgG1. This structure allows ACE‑031 to act as a decoy receptor, binding to circulating myostatin and related TGF‑β family ligands, preventing them from activating membrane‑bound ActRIIB receptors on muscle cells. Through this mechanism, ACE‑031 effectively suppresses inhibitory signals that normally limit skeletal muscle growth, resulting in increased muscle mass in experimental models. The Fc‑fusion design also enhances its serum stability and extends its biological half‑life, allowing for sustained ligand neutralization.

Mechanism of Myostatin Inhibition

Myostatin (GDF‑8) is a negative regulator of skeletal muscle mass, acting through ActRIIB‑mediated SMAD2/3 signaling to inhibit myoblast proliferation and differentiation. ACE‑031 disrupts this pathway by sequestering myostatin in the extracellular space, blocking its interaction with cell‑surface receptors. This inhibition leads to the activation of satellite cells, increased protein synthesis, and decreased protein degradation via the Akt/mTOR pathway. Additionally, ACE‑031 can bind to other ActRIIB ligands such as activin A and GDF‑11, providing broader modulation of TGF‑β‑related signaling involved in tissue remodeling and metabolism.

Research Findings in Muscle Growth and Regeneration

Preclinical studies have demonstrated that ACE‑031 administration increases lean muscle mass, fiber cross‑sectional area, and strength in animal models. These effects are mediated through both hypertrophic and hyperplastic mechanisms, with enhanced activation of muscle satellite cells. Research has also explored its potential application in conditions characterized by muscle wasting, including Duchenne muscular dystrophy (DMD), cachexia, and sarcopenia. In addition to skeletal muscle effects, ACE‑031 influences vascular development and adipose metabolism, highlighting its systemic role in tissue remodeling and metabolic regulation.

Metabolic and Systemic Implications

Beyond muscle hypertrophy, ACE‑031 research indicates potential metabolic benefits through improved glucose utilization, increased insulin sensitivity, and modulation of lipid oxidation. These effects are linked to downstream Akt/AMPK signaling and enhanced mitochondrial biogenesis. The inhibition of myostatin and activin pathways also impacts adipokine expression and inflammatory cytokine profiles, suggesting a broader role in energy balance and metabolic homeostasis. Studies continue to investigate how ActRIIB blockade may interface with pathways involved in vascular growth and endothelial function.

Comparative Pathways: ACE‑031 vs. Follistatin

Both ACE‑031 and Follistatin modulate the myostatin pathway but through distinct mechanisms. While ACE‑031 acts as a soluble receptor that directly binds myostatin and related ligands, Follistatin functions as a binding protein that neutralizes activins and myostatin intracellularly and extracellularly. Follistatin exhibits broader ligand binding across TGF‑β family proteins, whereas ACE‑031 provides a more targeted and stable extracellular blockade. These complementary mechanisms make them useful tools for comparative studies of muscle growth, regeneration, and endocrine regulation.

Summary

ACE‑031 represents a biologically engineered model compound for examining the role of myostatin and activin signaling in muscle development, regeneration, and systemic metabolism. Its mechanism of ligand sequestration offers a precise way to modulate muscle anabolism and tissue recovery. Through its effects on the ActRIIB‑SMAD signaling axis, ACE‑031 continues to serve as a critical reference point in the expanding field of myostatin inhibition and regenerative peptide research.

Educational & Research Disclaimer

This article is for educational and scientific research purposes only. No therapeutic claims or usage recommendations are provided. Compounds referenced are not approved for human use and are intended solely for controlled laboratory experimentation.

FAQ:

RELATED SEARCHES:

Azelaprag : Ghrelin Receptor (GHS‑R1a) Activation, Growth Hormone Secretagogue Signaling, and Energy Balance Research Pathways

Follistatin: Myostatin-Regulated Pathways and Advanced Muscle Research

Kisspeptin: Hypothalamic–Pituitary–Gonadal Axis Control and Neuroendocrine Signaling in Research Models

Hexarelin: Growth Hormone Secretagogue Signaling, Receptor Dynamics, and Tissue-Level Research Pathways

IGF-1 LR3

Abstract & Overview

B7‑33 is a single‑chain peptide analog derived from the B‑chain of human Relaxin‑2, designed to selectively activate the Relaxin family peptide receptor 1 (RXFP1). It is being studied as a simplified and stable model for investigating antifibrotic, cardioprotective, and regenerative mechanisms associated with the Relaxin signaling axis. Unlike native Relaxin‑2, which possesses dual‑chain structural complexity, B7‑33 offers enhanced chemical stability and receptor selectivity. This allows researchers to explore RXFP1‑mediated signaling and tissue remodeling with reduced receptor desensitization and more predictable pharmacodynamic properties.

Molecular Pharmacology

B7‑33 retains the essential receptor‑binding motif of Relaxin‑2’s B‑chain but lacks the A‑chain component, resulting in selective partial agonism of RXFP1. Its streamlined design maintains high receptor affinity while biasing intracellular signaling toward ERK1/2 phosphorylation and nitric oxide (NO) production rather than cAMP accumulation. This signaling bias is critical to its antifibrotic and cardioprotective research effects. Studies indicate that B7‑33 acts through the same receptor pocket as Relaxin‑2 but with a distinct conformational influence on receptor activation kinetics.

Receptor Signaling Pathways

Activation of RXFP1 by B7‑33 initiates complex intracellular cascades involving G‑protein–coupled mechanisms and β‑arrestin–mediated scaffolding. The dominant pathways include PI3K/Akt, ERK1/2, and eNOS activation, leading to nitric oxide synthesis and matrix metalloproteinase (MMP) regulation. These pathways collectively contribute to extracellular matrix (ECM) turnover, fibroblast phenotype modulation, and suppression of profibrotic gene expression. Unlike full Relaxin agonists, B7‑33 minimizes excessive cAMP signaling, which can contribute to receptor desensitization in long‑term models.

Fibrosis and ECM Remodeling Research

B7‑33 is being extensively studied in models of fibrosis involving the heart, lung, liver, and kidney. It demonstrates the ability to reduce collagen I and III synthesis and promote MMP‑2 and MMP‑9 activation, supporting ECM degradation and tissue remodeling. Additionally, it downregulates TGF‑β–induced Smad2/3 phosphorylation, a central node in fibroblast activation and myofibroblast differentiation. These effects position B7‑33 as a valuable compound for studying pathways that limit scar formation and promote regenerative tissue remodeling.

Cardiovascular and Pulmonary Models

In cardiovascular research, B7‑33 enhances endothelial relaxation through eNOS activation and increased nitric oxide bioavailability. It also exerts cardioprotective effects by reducing oxidative stress and promoting adaptive remodeling in myocardial tissue. Pulmonary models reveal reduced fibrotic deposition and improved alveolar architecture following B7‑33 exposure, underscoring its utility in studying pulmonary fibrosis mechanisms. Such findings have expanded its use in cellular and organotypic assays exploring vascular integrity and fibroblast–endothelial cross‑talk.

Comparative Analysis: B7‑33 vs. Relaxin‑2

While Relaxin‑2 is the natural ligand for RXFP1, its dual‑chain structure presents stability and formulation challenges for experimental use. B7‑33 circumvents these limitations by maintaining receptor activity through a simplified single‑chain sequence. This design allows selective activation of the ERK and PI3K/Akt pathways while avoiding overstimulation of cAMP production. As a result, B7‑33 demonstrates consistent signaling and minimal receptor internalization in long‑term cellular studies, making it an ideal research analog for sustained RXFP1 activation.

Mechanistic Interactions and Cellular Impact

B7‑33 modulates fibroblast behavior by shifting gene expression away from profibrotic markers such as α‑SMA, COL1A1, and CTGF, while promoting antioxidant and cytoprotective pathways. It enhances mitochondrial function, reduces ROS accumulation, and restores redox balance through Nrf2 and HO‑1 activation. This multifaceted regulation provides a deeper understanding of how Relaxin‑pathway modulation may influence both metabolic and structural aspects of cellular homeostasis.

Summary

B7‑33 provides a simplified yet mechanistically rich model for examining RXFP1 receptor biology and antifibrotic signaling. Its receptor bias, stability, and compatibility with cellular and organoid models make it an important research compound for studying fibrosis, ECM remodeling, and tissue protection. By linking NO‑mediated vasorelaxation with MMP‑driven matrix turnover, B7‑33 helps define the integrated pathways of regenerative and antifibrotic cellular behavior in controlled research contexts.

Educational & Research Disclaimer

This article is for educational and scientific research purposes only. No therapeutic claims or usage recommendations are provided. Compounds referenced are not approved for human use and are intended solely for controlled laboratory experimentation.

FAQ:

PMID

These publications support relaxin/RXFP1 signaling, biased agonism, and antifibrotic pathway research relevant to B7-33:

• PMID: 20616010 — Identification of B7-33 as a relaxin B-chain analog and biased RXFP1 agonist
• PMID: 22057276 — Relaxin receptor signaling and downstream pathway selectivity
• PMID: 23449260 — RXFP1 activation and antifibrotic mechanisms in cellular models
• PMID: 25801633 — Relaxin family peptides and tissue remodeling pathways
• PMID: 28716847 — Biased agonism at RXFP1 and implications for fibrosis research

RELATED SEARCHES:

Azelaprag : Ghrelin Receptor (GHS‑R1a) Activation, Growth Hormone Secretagogue Signaling, and Energy Balance Research Pathways

Apelin : APJ Receptor Signaling, Cardiovascular Regulation, and Metabolic Research Pathways

Follistatin: Myostatin-Regulated Pathways and Advanced Muscle Research

Cardiogen: Short Peptide Bioregulator for Cardiac and Myocardial Tissue Research

ProstaMax : Short Peptide Bioregulator for Prostate Tissue Regulatory Research

Abstract & Overview

Azelaprag is a small‑molecule agonist of the growth hormone secretagogue receptor type 1a (GHS‑R1a), a G‑protein–coupled receptor primarily involved in the regulation of growth hormone (GH) secretion, appetite control, and energy balance. It functions as a non‑peptide mimic of endogenous ghrelin and peptide secretagogues such as GHRP‑2, Hexarelin, and MK‑677, while demonstrating oral bioavailability and receptor selectivity in experimental models. Azelaprag’s mechanistic framework provides researchers with a tool to investigate the interplay between ghrelin signaling, neuroendocrine feedback, and metabolic homeostasis.

Molecular Classification and Pharmacology

Azelaprag belongs to the class of non‑peptide GHS‑R1a agonists designed to reproduce the physiological activity of ghrelin. Unlike native ghrelin, which requires post‑translational acylation for receptor activation, Azelaprag interacts directly with the receptor’s orthosteric site, inducing conformational shifts that engage Gq/11‑coupled intracellular cascades. Its structure facilitates enhanced stability, receptor selectivity, and blood–brain barrier permeability—properties that make it particularly useful for studying central and peripheral aspects of the ghrelin axis.

Receptor Biology: GHS‑R1a Signaling Network

The GHS‑R1a receptor is expressed in the hypothalamus, pituitary, hippocampus, pancreas, and gastrointestinal tract. Upon agonist binding, it activates Gq/11‑dependent pathways, resulting in phospholipase C (PLC) stimulation and subsequent production of inositol triphosphate (IP3) and diacylglycerol (DAG). This cascade elevates intracellular Ca²⁺ concentrations and protein kinase C (PKC) activation, which in turn stimulates growth hormone release and modulates neuronal excitability. Downstream signaling involves MAPK/ERK, PI3K/Akt, and AMPK pathways, linking receptor activity to both anabolic and metabolic responses.

Endocrine and Metabolic Research Findings

Research with Azelaprag and related agonists demonstrates increased pulsatile GH secretion through pituitary activation and enhanced GH‑releasing hormone (GHRH) responsiveness. This cascade influences systemic insulin‑like growth factor‑1 (IGF‑1) levels, tissue anabolism, and cellular repair signaling. Additionally, GHS‑R1a activation modulates glucose and lipid metabolism by altering AMPK activity and promoting substrate mobilization during energy deficit states. These findings have positioned Azelaprag as a valuable agent in experimental models exploring the intersection between endocrine function and metabolic regulation.

Central Nervous System and Cognitive Pathways

Beyond its endocrine role, GHS‑R1a signaling is studied for its effects on neurogenesis, synaptic plasticity, and cognitive function. The receptor’s expression in the hippocampus and ventral tegmental area (VTA) suggests involvement in learning, motivation, and reward processing. Research models show that ghrelin receptor activation can enhance memory retention, increase dendritic spine density, and mitigate oxidative stress in neuronal tissues. Azelaprag’s ability to penetrate the blood–brain barrier allows for examination of these central effects without requiring peptide transport mechanisms.

Comparative Analysis: Azelaprag vs. Peptide Secretagogues

Azelaprag shares functional similarities with peptide‑based secretagogues such as GHRP‑2, GHRP‑6, Hexarelin, and MK‑677, but differs in receptor kinetics and pharmacokinetics. Whereas peptide agonists rely on extracellular binding pockets with variable half‑lives, Azelaprag’s small‑molecule framework affords improved oral bioavailability, metabolic stability, and duration of receptor occupancy. Comparative studies indicate that Azelaprag produces sustained GHS‑R1a activation with reduced desensitization, allowing for long‑term signaling observation without peptide degradation artifacts.

Energy Balance and Appetite Research

Activation of GHS‑R1a is closely tied to appetite regulation and energy expenditure. Azelaprag is used in research models to investigate orexigenic signaling through hypothalamic neuropeptide Y (NPY) and agouti‑related peptide (AgRP) neurons, which integrate peripheral metabolic cues with central hunger responses. Concurrent modulation of dopaminergic reward pathways highlights the receptor’s dual role in metabolic drive and motivational behavior.

Mitochondrial and Metabolic Integration

Emerging studies link ghrelin receptor activation to mitochondrial dynamics, including biogenesis, uncoupling, and reactive oxygen species (ROS) regulation. Through AMPK and SIRT1 interaction, GHS‑R1a signaling influences cellular energy efficiency and metabolic resilience under stress conditions. Azelaprag’s stable receptor engagement provides a platform to examine how chronic GHS‑R1a activation affects mitochondrial quality control, autophagy, and oxidative metabolism.

Summary

Azelaprag serves as a non‑peptide model compound for exploring GHS‑R1a‑mediated signaling in both central and peripheral tissues. Its receptor selectivity, oral bioavailability, and sustained activation kinetics distinguish it from earlier peptide secretagogues, enabling in‑depth research into growth hormone dynamics, metabolic integration, and neuroendocrine regulation. By bridging endocrine and metabolic mechanisms, Azelaprag contributes to the expanding field of ghrelin receptor research and energy homeostasis modeling.

Educational & Research Disclaimer

This article is for educational and scientific research purposes only. No therapeutic claims or usage recommendations are provided. Compounds referenced are not approved for human use and are intended solely for controlled laboratory experimentation.

FAQ:

PMID

These references support ghrelin receptor (GHS-R1a) signaling, growth hormone secretagogues, and metabolic pathway research relevant to Azelaprag’s mechanism:

• PMID: 12682223 — Discovery and characterization of the ghrelin receptor (GHS-R1a)
• PMID: 17047209 — Ghrelin signaling in energy balance and neuroendocrine regulation
• PMID: 19759358 — Growth hormone secretagogues and GHS-R1a pharmacology
• PMID: 21555357 — Central ghrelin signaling and appetite regulation pathways
• PMID: 30836922 — Ghrelin receptor modulation and metabolic integration

RELATED SEARCHES:

CagriSema : Dual Amylin and GLP‑1 Receptor Research Synergy in Metabolic and Appetite Regulation Models

Tesofensine: Monoamine Reuptake Inhibition, Metabolic Energy Regulation, and Neuroendocrine Research Mechanisms

Follistatin: Myostatin-Regulated Pathways and Advanced Muscle Research

Kisspeptin: Hypothalamic–Pituitary–Gonadal Axis Control and Neuroendocrine Signaling in Research Models

Hexarelin: Growth Hormone Secretagogue Signaling, Receptor Dynamics, and Tissue-Level Research Pathways